Business
Valeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler®
Valeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler®.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler®\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nValeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler®\nCanada NewsWire\nMONTREAL, June 1, 2021\n\n\n\nPrivate payer health plan coverage in Canada for Enerzair Breezhaler and Atectura Breezhaler has reached 80% Reimbursement proceedings with publicly funded health plans ready to commence MONTREAL, June 1, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, announced today that private payer health plans currently covering 80% of privately insured lives in Canada have agreed to provide reimbursement for Enerzair Breezhaler and Atectura Breezhaler. \n\n \n \n \n \n \n \n\n \nEnerzair Breezhaler and Atectura Breezhaler are two new innovative asthma therapies which have been approved for use in Canada.  \n\"Asthma therapies are largely covered by private payers representing 50% of the total market. Reimbursement of both Enerzair and Atectura are now available for the majority of privately covered lives in Canada and reimbursement proceedings with public health plans are  ready to commence\", said Frederic Fasano, Valeo's President and Chief Operating Officer. \"Both drugs have demonstrated, in head-to-head compararison versus standard of care, significant clinical improvement of asthma related symptoms, lung function and rate of exacerbations. These strong clinical value propositions were key in achieving the current level of private coverage\". \nAbout Enerzair Breezhaler  \nEnerzair Breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid. This formulation combines the bronchodilation of indacaterol acetate (a LABA) and the gly...